Best Growth Hormone Peptides: Differences in Mechanism, Evidence, and Expected Results
There is no best growth hormone peptide. One compound in the category, tesamorelin, is FDA-approved, and only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Every other name marketed under this heading is compounded or unapproved. In healthy adults, raising growth hormone shifts body composition modestly and does not reliably improve strength.
Interest in these compounds has grown alongside a wider direct-to-consumer prescribing market, where the same telehealth mechanics now cover many unrelated categories. Providers such as Ro, Hims and Hers, and Henry Meds sell weight management and men’s health programs online, and HealthRX lists cash pricing for services as different as ED treatment. That normalization is worth keeping in mind, because the ease of ordering a compound says nothing about whether the published evidence supports taking it.
Two mechanism families sit under one marketing label
The compounds sold as growth hormone peptides work through two separate receptors, and the distinction explains most of what follows.
The first family copies growth hormone releasing hormone, the hypothalamic signal that tells the pituitary to release growth hormone. Sermorelin, tesamorelin, and CJC-1295 belong here. They act on the GHRH receptor and depend on a pituitary that still responds.
The second family acts on the ghrelin receptor instead. Ipamorelin, GHRP-2, GHRP-6, and hexarelin are in this group, along with the oral compound MK-677, which is not a peptide at all but a small molecule that mimics ghrelin. These agents work through a different pathway and can also affect appetite, cortisol, and glucose handling.
Both families raise growth hormone in a pulsatile pattern rather than flooding the system the way injected recombinant growth hormone does. That is the pharmacological argument for the class. It is not, by itself, evidence that any of them produces a benefit worth paying for.
Where each compound stands
| Compound | Mechanism family | US regulatory status | Human evidence that exists |
|---|---|---|---|
| Tesamorelin (Egrifta SV, Egrifta WR) | GHRH analog | FDA-approved for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy; the label states it is not indicated for weight loss management | Randomized placebo-controlled trials in that specific population |
| Sermorelin | GHRH analog | No current FDA-approved label appears in DailyMed; supplied as a compounded preparation | Older literature on growth hormone deficiency assessment and pediatric treatment |
| CJC-1295 | Long-acting GHRH analog | Not approved; its compounding bulk substance nomination was withdrawn after FDA described safety concerns | One early-phase study in healthy adults that measured hormone levels only |
| Ipamorelin | Ghrelin receptor agonist | Not approved; placed in FDA category 2 for 503B compounding | Preclinical characterization; little published human outcome data |
| GHRP-2 and GHRP-6 | Ghrelin receptor agonists | Not approved; both in FDA category 2 for 503B compounding | Short physiology studies of hormone secretion in volunteers |
| MK-677 (ibutamoren) | Oral secretagogue, not a peptide | Not approved; category 2 for both 503A and 503B compounding | A two-year randomized trial in healthy older adults |
| Hexarelin | Ghrelin receptor agonist | Not approved | Limited older human pharmacology work; no modern outcome trials |
What the published evidence actually reports
The cleanest read on expected outcomes does not come from the peptides at all. It comes from studies of growth hormone itself, because that is what these compounds are trying to raise.
A systematic review of randomized trials in healthy older adults found that growth hormone reduced fat mass and increased lean mass by roughly two kilograms each, with no significant change in body weight. Bone density and most lipid measures did not move. Participants given growth hormone were significantly more likely to develop soft tissue swelling, joint pain, carpal tunnel syndrome, and gynecomastia, and somewhat more likely to develop impaired fasting glucose or diabetes. The authors concluded it cannot be recommended as an antiaging therapy.
A companion review of trials in physically fit young adults found the same lean mass increase, but strength and exercise capacity did not improve, lactate during exercise rose in most studies that measured it, and swelling and fatigue were more common. The stated conclusion was that claims of performance enhancement are not supported by the literature.
The secretagogues themselves have thinner files. The two-year randomized trial of MK-677 in healthy older adults did increase fat-free mass by about a kilogram against a placebo decline, but visceral fat did not change, body weight rose, fasting glucose rose, insulin sensitivity fell, and the added fat-free mass produced no measurable change in strength or physical function. The published CJC-1295 study measured growth hormone and IGF-I concentrations over weeks, not body composition or clinical outcomes. A 30-day study of GHRP-2 in older adults likewise reported sustained hormone elevation as its finding.
Tesamorelin is the exception, and the reason it is approved. A randomized trial in adults with HIV and abdominal fat accumulation showed real reductions in visceral adipose tissue and liver fat over six months. That result belongs to that population and that indication.
Higher hormone levels are not the same as an outcome
Almost every marketing claim here rests on a substitution: a compound raised growth hormone or IGF-I, therefore it will do what growth hormone is imagined to do. The MK-677 trial is the clearest counterexample. Hormone levels reached the young-adult range, lean mass increased, and strength and function stayed flat.
Access reflects that gap more than it reflects the science. Tesamorelin moves through specialty pharmacy for its labeled use, while the rest of the category reaches patients through compounding pharmacies working with prescribers, increasingly by telehealth. Clinics such as Defy Medical and Marek Health have built practices around hormone and peptide prescribing, and cash-pay platforms including FormBlends operate in the same space with published pricing for physician-supervised compounded medication. What distinguishes providers here is not the menu of molecules, which is broadly similar, but whether a real evaluation precedes a shipment.
Compounded does not mean reviewed
Compounded preparations are not FDA-approved and are not assessed for safety, effectiveness, or manufacturing quality before sale. FDA has flagged several substances in this category as carrying potential immunogenicity risk from aggregation and peptide-related impurities, and has noted that unnatural amino acids in some of them complicate characterization.
The sport question is settled
Growth hormone, growth hormone releasing factors, and growth hormone secretagogues are prohibited at all times under the World Anti-Doping Code, in and out of competition. That covers sermorelin, tesamorelin, CJC-1295, ipamorelin, the GHRPs, hexarelin, and ibutamoren. Anyone in a tested sport should treat the whole category as off limits regardless of how it is prescribed.
Frequently asked questions
Is any growth hormone peptide FDA-approved?
Tesamorelin is, under the brand names Egrifta SV and Egrifta WR, for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The label states directly that it is not indicated for weight loss management. No other compound in the category holds an approval.
Which family produces better outcomes, GHRH analogs or ghrelin agonists?
Neither has been shown superior for outcomes in healthy adults, because outcome trials comparing them do not exist. The published work measures hormone concentrations. Choosing between families on efficacy grounds means choosing on data that has not been collected.
Will these build muscle or improve athletic performance?
The evidence base for growth hormone itself found increased lean mass without improvement in strength or exercise capacity, and higher rates of swelling and fatigue. Secretagogue studies show the same pattern where they measured function at all, which was rarely.
Is MK-677 a peptide?
No. Ibutamoren is an orally active small molecule that acts on the ghrelin receptor. It is grouped with peptides commercially because it raises growth hormone, but it is chemically different, is not approved, and FDA has flagged a congestive heart failure safety signal from a terminated trial.
What did the CJC-1295 study actually show?
That subcutaneous doses produced sustained, dose-dependent rises in growth hormone and IGF-I in healthy adults over several weeks, with a long half-life. It was a pharmacology study. It did not assess body composition, strength, or any clinical endpoint.
